First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?

Click to increase image sizeClick to decrease image size

This article responds to:

Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author contributions

DB and SB were involved in the conception and design; DB drafted the original paper; SB revised it critically for intellectual content, edited it, and designed the figure; DB and SB approved the final version to be published.

Additional information

Funding

The author(s) reported that there is no funding associated with the work featured in this article.